Entrepreneur First is the place where the ambitious come together to build globally important technology companies. Through our platform running in 6 cities across 3 continents, we invest in high-potential individuals to help them meet their co-founder, develop their ideas and secure funding from leading investors in the shortest possible time.   We have built over 300 companies from scratch; have over 5000 alumni worldwide; and our portfolio is valued at over $5bn. EF companies include Tractable (Computer Vision, currently valued at $1bn as of June 2021), Magic Pony Technology (AI, acquired by Twitter for a reported $150m), Represent (social commerce, acquired by CustomInk), BloomsburyAI (acquired by Facebook), Cleo (fintech), OpenCosmos (space), CloudNC (manufacturing), Transcelestial (satellite communications) and many more. We're backed by some of the world's best tech founders and investors, including Reid Hoffman (LinkedIn), Greylock Partners, Founders Fund, Demis Hassabis (Google Deepmind) and Taavet Hinrikus (Wise). For more information about Entrepreneur First, visit www.joinef.com.

Entrepreneur First

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies. With a particular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas. Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Angels in MedCity

Investors in a broad range of early stage businesses. The majority have been in the biomedical space, but also in tech businesses.

Anvil Partners

DigitalHealth.London Accelerator programme is uniquely positioned to provide in-depth knowledge of the NHS to a cohort of high potential small and medium sized businesses (SMEs). The Accelerator aims to speed up the adoption of innovation at scale, ensuring that greater numbers of patients benefit from emerging new technology, more rapidly.  It’s the first programme of its kind, based in London, which draws upon a number of key founding and strategic partners, who together bring a rich and diverse collateral of resources and expertise across healthcare, research, innovation, digital health and tech.

DigitalHealth.London Accelerator

Atomico is an international investment firm that focuses on helping disruptive technology companies scale globally. It partners with technology founders at the Seed stage and beyond with a particular focus on Europe, leveraging deep operational experience to supercharge their growth. The company's team of founders, investors, and operational leaders have been responsible for global expansion, hiring, and marketing at companies from Skype, Google, and Twitter to Wise and Snowflake. It specializes in seed, startup, Series A, early venture, mid venture, late venture, emerging growth, and growth capital investments.   Atomico was founded in 2006 and is headquartered in London, England, with offices in Paris, Berlin, and Stockholm

Atomico

LocalGlobe is a UK-based venture capital firm that focuses on seed and impact investments. Seeding ambitious UK founders since 1999 inc Citymapper, Improbable, Lovefilm, Moo, Tweetdeck, Transferwise, and Zoopla.

LocalGlobe

Trusted Insight is an LP network that provides institutional investors with curated news, jobs, rankings, online and offline events, and a forum.  With over 140,000 members on the platform controlling over $18 Trillion in assets, Trusted Insight is the fastest growing and most trusted alternative platform. 30,000 institutional investors engage with Trusted Insight each week. They are actively investing in alternative assets, primarily private equity, hedge funds, real estate and private companies.  Founded by Alex Bangash, Trusted Insight started in 2010 and is venture-funded and revenue-producing. Its investors were the first investors or founders of Facebook, LinkedIn, Mint, Match.com, and Blackstone, among others. The company has offices in NYC and San Francisco.

Trusted Insight

Encore Capital is owned and managed by its partners who are the key decision makers. They have over £60m of committed funding, and are seeking to grow the existing portfolio by investing in established businesses with proven growth potential.

Encore Capital

Lakestar is a venture capital firm investing in technology companies led by exceptional entrepreneurs. Early investments included Skype, Spotify, Facebook, and Airbnb. Since raising the first fund in 2013, Lakestar manages an aggregated volume of over EUR 1bn across three early-stage funds, and more recently a growth fund.  The company has expanded and broadened its portfolio and holds investments in the likes of Opendoor, Oscar, GetYourGuide, Glovo, Sender, Eigen, Five, Revolut, and Hometogo to name a few. Lakestar has a presence in Berlin, Zurich, and London. Lakestar helps companies to identify new markets and expand into them rapidly, with a focus on the US and Europe. The team advises and supports portfolio companies in business development, recruitment, technology, and marketing. The investments range from early-stage companies to those in their growth stage.

Lakestar

Latitude Ventures is the series B+ sister fund to UK-based seed fund LocalGlobe. Latitude invests in emerging break-out companies from LocalGlobe, as well as more widely in the most ambitious founders. Latitude and LocalGlobe have been early investor in iconic companies including Transferwise, Zoopla, Improbable, Robinhood, Citymapper and Secret Escapes, as well as emerging stars including Tessian, TravelPerk, Flow Commerce and Raisin.

Latitude

British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds and start ups, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk. As well as providing our own funding we work to encourage more investors to make allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns. Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.

British Patient Capital

Accurx

Accurx is where conversations happen with and about patients. Through one, easy-to-use platform, we help everyone involved in a patient’s care to communicate and collaborate. Whether you’re a patient or a healthcare professional, Accurx lets you connect seamlessly with the people you need to. You can use Accurx to: send SMS messages and medical surveys, provide appointment reminders and referrals, hold video consultations, and manage virtual wards, outpatient clinics and follow-up pathways. Accurx is used by 98% of GP practices and in 50% of NHS trusts.

<div><p>AccuRx is a telehealth platform that enables patients to communicate with general physicians via text and video consultations. The company also provides other tools such as patient triage, questionnaires on symptoms, digital documents, and Covid-19 vaccine booking. The platform has facilitated more than 40 million patients for more than 7,000 general practices, as of September 2021.</p></div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

AccuRx

<div>
  <p>
    AccuRx is a telehealth platform that enables patients to communicate with general physicians via text and video consultations. The company also provides other tools such as patient triage, questionnaires on symptoms, digital documents, and Covid-19 vaccine booking. The platform has facilitated more than 40 million patients for more than 7,000 general practices, as of September 2021.
  </p>
</div>


<div>
  <p>
    Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
  </p>
  <p>
    In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
  </p>
  <p>
  </p>
</div>


Nice Healthcare

<div>
  <p>
    Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications. 
  </p>
  <p>
    Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.
  </p>
</div>


Amicomed

<div>
  <p>
    Winston is a men&rsquo;s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients. 
  </p>
  <p>
    The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.
  </p>
</div>


Winston

<div>
  <p>
    Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram functionality to detect heart rhythm abnormalities using artificial intelligence (AI) algorithms. In 2020, the company obtained 501(k) FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations. 
  </p>
  <p>
    The company operates on a fee per unit B2B2C model and a D2C model, where it provides its technology to medical practitioners or patients for diagnostic purposes.
  </p>
  <p>
    In February 2023, Eko 
    <a href="https://sp-edge.com/updates/16677">
      launched SENSORA
    </a>
    , a cardiac disease detection platform that combines the company&rsquo;s existing digital stethoscopes with a machine learning-based platform. The platform enables primary care physicians to detect structural murmurs and assess heart arrhythmias by using a database of heart sounds to compare and identify anomalies in a patient's heart beat. 
  </p>
  <p>
    In April 2024, Eko 
    <a href="https://sp-edge.com/updates/28111">
      obtained FDA 510(k) clearance
    </a>
     for its AI-aided cardiac tool, Eko Low Ejection Fraction Tool (ELEFT). The tool is designed to assist providers in early detection of low ejection fraction, a significant sign of heart failure.
  </p>
  <p>
    <b>Funding and financials</b>
  </p>
  <p>
    In March 2022, raised a further USD 30 million in an extension to its Series C round, which began November 2020. The total funds raised by the company stood at USD 126 million as of March. These funds have been allocated to support further commercialization efforts and develop new products for the company.
  </p>
  <p>
  </p>
  <p>
  </p>
  <p>
  </p>
</div>


<div>
  <p>
    Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
  </p>
  <p>
    The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care,  wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
  </p>
  <p>
    <b>Key Customers and partnerships</b>
  </p>
  <p>
    Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
  </p>
  <p>
    <b>Fundings and financials</b>
  </p>
  <p>
    As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
  </p>
  <p>
    In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
    an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
     
    Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
    <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
      <u>acquired by financial services company Sun Life Financial</u>
    </a>
     for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
  </p>
  <p>
  </p>
</div>


Dialogue

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers. 

AccuRx

Telehealth

Key stats

Recent Updates

Supercritical raises USD 2.7 million in pre-seed funding

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless